Ken Griffin Infla Rx N.V. Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Infla Rx N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 32,700 shares of IFRX stock, worth $27,141. This represents 0.0% of its overall portfolio holdings.

Number of Shares

32,700

Previous 33,600 2.68%

Holding current value

$27,141

Previous $34,000 26.47%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.02 - $2.62 $389,546 - $1 Million	381,908 Added 750.1%	432,822 $441,000
Q4 2024 Feb 14, 2025	BUY	$1.38 - $2.64 $38,602 - $73,848	27,973 Added 121.93%	50,914 $126,000
Q3 2024 Nov 14, 2024	SELL	$1.34 - $1.73 $52,908 - $68,307	-39,484 Reduced 63.25%	22,941 $35,000
Q2 2024 Aug 14, 2024	SELL	$1.18 - $1.74 $41,959 - $61,872	-35,559 Reduced 36.29%	62,425 $108,000
Q1 2024 May 15, 2024	BUY	$1.47 - $2.03 $125,127 - $172,795	85,121 Added 661.75%	97,984 $150,000
Q4 2023 Feb 14, 2024	SELL	$1.25 - $2.75 $6 - $13	-5 Reduced 0.04%	12,863 $20,000
Q3 2023 Nov 14, 2023	BUY	$2.66 - $4.33 $34,228 - $55,718	12,868 New	12,868 $38,000
Q1 2023 May 15, 2023	SELL	$1.66 - $3.1 $15,356 - $28,678	-9,251 Reduced 95.74%	412 $0
Q4 2022 Feb 14, 2023	BUY	$2.11 - $3.25 $20,388 - $31,404	9,663 New	9,663 $29,000
Q2 2022 Aug 15, 2022	SELL	$0.78 - $1.9 $22,903 - $55,789	-29,363 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.83 - $4.48 $48,881 - $119,665	-26,711 Reduced 47.64%	29,363 $54,000
Q4 2021 Feb 14, 2022	BUY	$2.35 - $5.58 $106,309 - $252,428	45,238 Added 417.48%	56,074 $266,000
Q2 2021 Aug 16, 2021	BUY	$2.72 - $4.04 $29,473 - $43,777	10,836 New	10,836 $32,000
Q1 2021 May 17, 2021	SELL	$3.62 - $6.34 $102,341 - $179,238	-28,271 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$3.82 - $5.32 $2 Million - $2.78 Million	-523,003 Reduced 94.87%	28,271 $143,000
Q1 2020 May 15, 2020	BUY	$2.65 - $6.08 $1.18 Million - $2.71 Million	445,472 Added 421.04%	551,274 $2.11 Million
Q4 2019 Feb 14, 2020	BUY	$2.2 - $4.54 $12,907 - $26,636	5,867 Added 5.87%	105,802 $419,000
Q2 2019 Aug 14, 2019	BUY	$3.06 - $51.61 $14,810 - $249,792	4,840 Added 5.09%	99,935 $316,000
Q1 2019 May 15, 2019	BUY	$31.16 - $48.62 $2.02 Million - $3.15 Million	64,801 Added 213.91%	95,095 $0
Q4 2018 Feb 14, 2019	SELL	$23.33 - $36.37 $1.15 Million - $1.79 Million	-49,293 Reduced 61.94%	30,294 $1.1 Million
Q3 2018 Nov 13, 2018	SELL	$29.34 - $35.0 $3.24 Million - $3.87 Million	-110,593 Reduced 58.15%	79,587 $0
Q2 2018 Aug 10, 2018	BUY	$27.33 - $41.46 $1.54 Million - $2.33 Million	56,309 Added 42.06%	190,180 $0
Q1 2018 May 11, 2018	BUY	$20.21 - $32.0 $2.71 Million - $4.28 Million	133,871 New	133,871 $3.86 Million

Others Institutions Holding IFRX

# of Institutions

Shares Held

17.5M

Call Options Held

32.7K

Put Options Held

View Full List

About InflaRx N.V.

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $36.7M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

More about IFRX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account